JP2007526759A5 - - Google Patents

Download PDF

Info

Publication number
JP2007526759A5
JP2007526759A5 JP2006525779A JP2006525779A JP2007526759A5 JP 2007526759 A5 JP2007526759 A5 JP 2007526759A5 JP 2006525779 A JP2006525779 A JP 2006525779A JP 2006525779 A JP2006525779 A JP 2006525779A JP 2007526759 A5 JP2007526759 A5 JP 2007526759A5
Authority
JP
Japan
Prior art keywords
nucleic acid
tumor
associated antigen
group
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006525779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007526759A (ja
JP5007123B2 (ja
Filing date
Publication date
Priority claimed from DE10341812A external-priority patent/DE10341812A1/de
Application filed filed Critical
Publication of JP2007526759A publication Critical patent/JP2007526759A/ja
Publication of JP2007526759A5 publication Critical patent/JP2007526759A5/ja
Application granted granted Critical
Publication of JP5007123B2 publication Critical patent/JP5007123B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006525779A 2003-09-10 2004-09-10 腫瘍において示差的に発現される遺伝子産物およびこの使用 Expired - Lifetime JP5007123B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10341812A DE10341812A1 (de) 2003-09-10 2003-09-10 Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10341812.1 2003-09-10
PCT/EP2004/010164 WO2005026205A2 (de) 2003-09-10 2004-09-10 Differentiell in tumoren exprimierte genprodukte und deren verwendung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011205112A Division JP2012050441A (ja) 2003-09-10 2011-09-20 腫瘍において示差的に発現される遺伝子産物およびこの使用

Publications (3)

Publication Number Publication Date
JP2007526759A JP2007526759A (ja) 2007-09-20
JP2007526759A5 true JP2007526759A5 (enExample) 2011-03-31
JP5007123B2 JP5007123B2 (ja) 2012-08-22

Family

ID=34258548

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006525779A Expired - Lifetime JP5007123B2 (ja) 2003-09-10 2004-09-10 腫瘍において示差的に発現される遺伝子産物およびこの使用
JP2011205112A Pending JP2012050441A (ja) 2003-09-10 2011-09-20 腫瘍において示差的に発現される遺伝子産物およびこの使用
JP2012154564A Expired - Lifetime JP5711698B2 (ja) 2003-09-10 2012-07-10 腫瘍において示差的に発現される遺伝子産物およびこの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011205112A Pending JP2012050441A (ja) 2003-09-10 2011-09-20 腫瘍において示差的に発現される遺伝子産物およびこの使用
JP2012154564A Expired - Lifetime JP5711698B2 (ja) 2003-09-10 2012-07-10 腫瘍において示差的に発現される遺伝子産物およびこの使用

Country Status (8)

Country Link
US (1) US8765389B2 (enExample)
EP (7) EP3095791B1 (enExample)
JP (3) JP5007123B2 (enExample)
AU (1) AU2004272270B2 (enExample)
CA (1) CA2538528C (enExample)
DE (1) DE10341812A1 (enExample)
ES (1) ES2663242T3 (enExample)
WO (1) WO2005026205A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1795596A1 (en) * 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
EP1911851A1 (en) 2006-10-12 2008-04-16 Ganymed Pharmaceuticals AG Compositions and methods for therapy and diagnosis of cancer and cancer metastasis
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
EP2108701A1 (en) * 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
JP5565723B2 (ja) * 2009-04-07 2014-08-06 学校法人北里研究所 抗ｄｃｄモノクローナル抗体
BR112013006718B1 (pt) * 2010-09-20 2021-12-07 Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo
WO2013164787A1 (en) 2012-05-02 2013-11-07 Helse Stavanger As Assay methods for diagnosing and monitoring cancer
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
WO2015140567A1 (en) * 2014-03-21 2015-09-24 Immunocore Limited Tumor associated antigens derived from traip
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
US11308700B2 (en) 2020-04-06 2022-04-19 Saudi Arabian Oil Company Augmented reality visualization of underground pipelines using geospatial databases and KM markers
WO2021251842A1 (en) * 2020-06-08 2021-12-16 Qatar Foundation For Education, Science And Community Development Targeting of lactate dehydrogenase c, methods of preparing same, and methods of using same in combination with anti-cancer treatments
TW202320842A (zh) 2021-07-29 2023-06-01 德商拜恩技術股份公司 用於治療黑色素瘤之組合物及方法
WO2025264662A1 (en) 2024-06-18 2025-12-26 BioNTech SE Compositions and methods for treatment of melanoma

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0270056A1 (en) * 1986-12-01 1988-06-08 Northwestern University Human LDH-C 4cDNA sequences encoding antigenic regions
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AU1726199A (en) * 1997-12-31 1999-07-19 Chiron Corporation Metastatic cancer regulated gene
CA2320427A1 (en) 1998-02-12 1999-08-19 Incyte Pharmaceuticals, Inc. Human receptor proteins
US6262333B1 (en) * 1998-06-10 2001-07-17 Bayer Corporation Human genes and gene expression products
JP2002523088A (ja) * 1998-08-31 2002-07-30 バイエル コーポレイション 結腸癌において示差的に発現されるヒト遺伝子
HK1041025A1 (zh) * 1998-12-23 2002-06-28 Corixa Corporation 用於結腸癌的免疫治療和診斷的化合物及其使用方法
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
DE19936563A1 (de) 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
EP1208191A4 (en) * 1999-08-13 2003-12-10 Human Genome Sciences Inc 13 PROTEINS ASSOCIATED WITH COLON CANCER AND HUMAN COLON
AU7721500A (en) * 1999-09-29 2001-04-30 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1305404A2 (en) 2000-07-28 2003-05-02 Incyte Genomics, Inc. Protein phosphatases
US20020160382A1 (en) * 2000-10-11 2002-10-31 Lasek Amy W. Genes expressed in colon cancer
WO2002062946A2 (en) 2000-12-08 2002-08-15 Duke University Identification of novel ms4a gene family members expressed by hematopoietic cells
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
EP1222928A3 (en) 2001-01-16 2003-11-05 Universität Zürich Institut für Medizinische Virologie Pharmaceutical compositions for treating or preventing cancer, especially melanoma
WO2002081638A2 (en) * 2001-04-06 2002-10-17 Origene Technologies, Inc Prostate cancer expression profiles
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1594447A2 (en) * 2002-10-02 2005-11-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2005052182A2 (en) * 2003-11-26 2005-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method of analyzing plasma membrane protein content of cells

Similar Documents

Publication Publication Date Title
JP2007526759A5 (enExample)
JP6196338B2 (ja) 診断および治療のための腫瘍関連抗原の同定
JP2007537197A5 (enExample)
JP2005519608A5 (enExample)
JP2007506417A5 (enExample)
JP2008537546A5 (enExample)
JP2005526494A5 (enExample)
JP2010047597A5 (enExample)
JP2008508861A5 (enExample)
CN1646692B (zh) 在肿瘤中差异表达的基因产物及其用途
US20210061876A1 (en) T cell receptors for tumor specific proteasome splice variants and uses thereof
CN107556367B (zh) 一种肿瘤免疫治疗预测生物标志物pd-l2靶向多肽及其应用
JP2005507648A5 (enExample)
US8722350B2 (en) Methods and compositions for categorizing patients
KR102574799B1 (ko) 마약 중독 또는 금단증상 진단용 바이오마커 조성물 및 마약 중독 또는 금단증상 진단용 키트
EP3354658A1 (en) Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases
MXPA06012446A (es) Metodos y composiciones para el tratamiento de enfermedades poliquisticas.
US20030170755A1 (en) Tumor-associated antigen RHAMM
JP2012525121A5 (enExample)
US12209137B2 (en) Antigen binding proteins specifically binding CT45
WO2003102028A1 (fr) Proteine induite par le gene rb1 (rb1cc1) et gene
JP2006516888A5 (enExample)
AU2009212789B2 (en) Ninjurin-1 and/or MCAM Modulation and Uses Thereof
KR20220109049A (ko) 허혈성 질환 진단 또는 예후 진단용 바이오마커
Yuvaraj et al. Targeting of complement regulatory proteins to cellular glycosaminoglycans by splicing binding domains of tissue factor pathway inhibitor